Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

177 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study.
Duchmann M, Micol JB, Duployez N, Raffoux E, Thomas X, Marolleau JP, Braun T, Adès L, Chantepie S, Lemasle E, Berthon C, Malfuson JV, Pautas C, Lambert J, Boissel N, Celli-Lebras K, Caillot D, Turlure P, Vey N, Pigneux A, Recher C, Terré C, Gardin C, Itzykson R, Preudhomme C, Dombret H, de Botton S. Duchmann M, et al. Among authors: de botton s. Blood. 2021 May 20;137(20):2827-2837. doi: 10.1182/blood.2020010165. Blood. 2021. PMID: 33881523 Free article.
Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA).
Preudhomme C, Sagot C, Boissel N, Cayuela JM, Tigaud I, de Botton S, Thomas X, Raffoux E, Lamandin C, Castaigne S, Fenaux P, Dombret H; ALFA Group. Preudhomme C, et al. Among authors: de botton s. Blood. 2002 Oct 15;100(8):2717-23. doi: 10.1182/blood-2002-03-0990. Blood. 2002. PMID: 12351377 Free article.
Are PU.1 mutations frequent genetic events in acute myeloid leukemia (AML)?
Lamandin C, Sagot C, Roumier C, Lepelley P, De Botton S, Cosson A, Fenaux P, Preudhomme C. Lamandin C, et al. Among authors: de botton s. Blood. 2002 Dec 15;100(13):4680-1. doi: 10.1182/blood-2002-08-2563. Blood. 2002. PMID: 12453885 Free article. No abstract available.
Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype.
Boissel N, Renneville A, Biggio V, Philippe N, Thomas X, Cayuela JM, Terre C, Tigaud I, Castaigne S, Raffoux E, De Botton S, Fenaux P, Dombret H, Preudhomme C. Boissel N, et al. Among authors: de botton s. Blood. 2005 Nov 15;106(10):3618-20. doi: 10.1182/blood-2005-05-2174. Epub 2005 Jul 26. Blood. 2005. PMID: 16046528 Free article.
Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group.
Adès L, Chevret S, Raffoux E, de Botton S, Guerci A, Pigneux A, Stoppa AM, Lamy T, Rigal-Huguet F, Vekhoff A, Meyer-Monard S, Maloisel F, Deconinck E, Ferrant A, Thomas X, Fegueux N, Chomienne C, Dombret H, Degos L, Fenaux P; European Acute Promyelocytic Leukemia Group. Adès L, et al. Among authors: de botton s. J Clin Oncol. 2006 Dec 20;24(36):5703-10. doi: 10.1200/JCO.2006.08.1596. Epub 2006 Nov 20. J Clin Oncol. 2006. PMID: 17116939 Clinical Trial.
Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial.
Gardin C, Turlure P, Fagot T, Thomas X, Terre C, Contentin N, Raffoux E, de Botton S, Pautas C, Reman O, Bourhis JH, Fenaux P, Castaigne S, Michallet M, Preudhomme C, de Revel T, Bordessoule D, Dombret H. Gardin C, et al. Among authors: de botton s, de revel t. Blood. 2007 Jun 15;109(12):5129-35. doi: 10.1182/blood-2007-02-069666. Epub 2007 Mar 6. Blood. 2007. PMID: 17341661 Free article. Clinical Trial.
177 results